Three cases in which new or persistent mutations detected by ccfDNA predicted subsequent relapse. In cases UPN21 and UPN4, new mutation(s) detected by ccfDNA while in remission preceded overt morphologic relapse. In case UPN2, persistent mutations after allogeneic stem cell transplant were detected 1 month prior to morphologic relapse. Treatment regimens are shown below the x-axis. The y-axis represents percentage of bone marrow blasts and VAFs in the ccfDNA and/or bone marrow. The solid line represents ccfDNA VAFs over time. The dotted vertical line represents the time of relapse. The shaded gray area represents bone marrow blasts over the course of therapy and monitoring. CLIA, cladribine, idarubicin, and cytarabine; FLAG+IDA, fludarabine, cytarabine, granulocyte-stimulating factor, and idarubicin.